<DOC>
	<DOCNO>NCT02986490</DOCNO>
	<brief_summary>Background : Antipsychotics induce metabolic disorder obesity , hyperglycemia , dyslipidemia metabolic syndrome . It observe treatment antipsychotic could accompany decrease concentration serum magnesium . Low serum concentration magnesium potentially risk factor cardiac sudden death ( Peacock , 2010 ) . Hypotheses link magnesium pathogenesis cardiovacuscular diseases multiple . Also , seem exist close relationship magnesium carbohydrate metabolism . Most study subject generally study plasmatic magnesium . Objective : Describe relationship change serum intra-erythrocyte magnesium cardiometabolic risk patient innitiating antipsychotic treatment . A secondary objective specify frequency , magnitude time onset change plasma magnesium level antipsychotic treatment . Methods : This pilot single-center prospective cohort . After inclusion , patient status ( include magnesium level ) evaluate ( 1 3 month treatment ) status define exposure criterion . Included patient follow 1 year cardiometabolic marker measure . Population : patient 18 year old schizophrenia schizoaffective disorder bipolar disorder , naive antipsychotic treatment 3 month require introduction antipsychotic drug therapy . Patients recruit consultation stay care unit Adult Psychiatry Unit Montpellier University Hospital . Factor study : serum intra-erythrocytic magnesium level begin antipsychotic treatment measure unique analyzer center . Changes level hypomagnesemia expect treatment determine exposure group . Outcome : cardiometabolic risk marker measure begin treatment fast blood glucose , fast plasma insulin , HOMA-IR [ Ins ( uU / mL ) x Gly ( mmol / L ) / 22.5 ] , lipid profile ( total cholesterol , LDL , HDL ) , BMI , waist circumference ECG ( QTc ) . Cofactors : age , sex , personal family medical history , blood pressure , smoking , diet , physical activity , psychiatric disease , Global Impressions , anti-psychotic treatment comedications . Perspectives : show decrease magnesium level observe among patient start antipsychotic treatment associate deterioration cardiometabolic risk marker . The demonstration association could explain least part increase cardiovascular risk observe population . In long term , result study would argue implementation intervention research project study magnesium supplementation minimize metabolic effect antipsychotic medication .</brief_summary>
	<brief_title>Magnesium Variations Cardiometabolic Risk Patients With Antipsychotic Drugs</brief_title>
	<detailed_description>This pilot single-center prospective cohort . After inclusion , patient status ( include magnesium level ) evaluate ( 1 3 month treatment ) status define exposure criterion . Included patient follow 1 year cardiometabolic marker measure . Patients recruit consultation stay care unit Adult Psychiatry Unit Montpellier University Hospital .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Inclusion criterion : Patient severe mental illness ( schizophrenia disorder chronic psychotic , schizoaffective disorder bipolar disorder . Patient naive antipsychotic treatment stop 3 month ( 6 month antipsychotic action extend ) require introduction antipsychotic therapy Patient inform accept propose followup ( his/her legal representative ) Patient available one year monitoring Patient affiliate beneficiary social security insurance Exclusion criterion : patient 's opposition Pregnant breastfeeding patient Patients antipsychotic treatment stop less 3 month ( 6 month antipsychotic prolonged action )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Mental disorder</keyword>
	<keyword>Antipsychotic agent</keyword>
	<keyword>Magnesium</keyword>
	<keyword>Cardiovascular risk factor</keyword>
	<keyword>Metabolic syndrome</keyword>
</DOC>